TGFBR1 and hepatocellular carcinoma: The TGF-β-receptor-1 (TGFBR1) inhibitor LY2157299 (“galunisertib”) (currently investigated as potential therapeutic option in HCC in clinical trials [36,37]) antagonized TGF-β1-mediated upregulation of Snail and PDE6D (Figure 5D; Figure S2).